Association between allopurinol and mortality in heart failure patients: a long-term follow-up study
Summary Aims: The aim of the study was to explore the long‐term effect of allopurinol on mortality and cardiovascular hospitalisations in heart failure (HF) patients. Methods: This is a population‐based cohort study using a record‐linkage database in Tayside, Scotland. A total of 4785 HF patients...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2009-09, Vol.63 (9), p.1327-1333 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1333 |
|---|---|
| container_issue | 9 |
| container_start_page | 1327 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 63 |
| creator | Wei, L. Fahey, T. Struthers, A. D. MacDonald, T. M. |
| description | Summary
Aims: The aim of the study was to explore the long‐term effect of allopurinol on mortality and cardiovascular hospitalisations in heart failure (HF) patients.
Methods: This is a population‐based cohort study using a record‐linkage database in Tayside, Scotland. A total of 4785 HF patients (4260 non‐users, 267 incident users and 258 prevalent users) were studied between 1993 and 2002.
Results: Compared with non‐users, low‐dose users in the incident group had a significant increased risk of all‐cause mortality, cardiovascular mortality and cardiovascular recurrence (adjusted HR, 1.60, 95%CI 1.26–2.03; 1.70, 1.29–2.23 and 1.44, 1.01–2.07). For the prevalent users, the adjusted HR were 1.27, 0.98–1.64; 1.43, 1.07–1.90 and 1.27, 0.91–1.76 respectively. There was no increased risk of outcome for high‐dose users when compared with non‐users (adjusted HR, 1.18, 0.84–1.66; 1.14, 0.76–1.71 and 1.36, 0.88–2.10 for the incident users, and 0.86, 0.64–1.15; 0.90, 0.64–1.26; and 1.27, 0.93–1.74 for the prevalent users respectively). High‐dose allopurinol was associated with reduced risk of all‐course mortality for prevalent users when compared with low‐dose (adjusted HR 0.65, 95%CI 0.42–0.99).
Conclusions: The prevalent high‐dose allopurinol use had a lower risk of mortality than the prevalent low‐dose use suggesting that allopurinol may be of benefit in HF patients. |
| doi_str_mv | 10.1111/j.1742-1241.2009.02118.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733969273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20796827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6118-210fd88fc79f34d6140d4bfc605b0c91f60f0edd36b9203e9dfbd039f27c30e23</originalsourceid><addsrcrecordid>eNqNkV-L1DAUxYMo7u7oV5AgqE-t-dOmjQ8L66yzrgwqq-JjSJtEM6ZNTVpm5tubOsMIPoh5uRfyO4dzOQBAjHKc3stNjquCZJgUOCcI8RwRjOt8dw-cnz7up52yOisRxWfgIsYNQqQsa_QQnGHOOGaYnQN1FaNvrRyt72Gjx63WPZTO-WEKtvcOyl7BzodROjvuoe3hdy3DCI20bgoaDkmp-zG-ghI633_LRh06aHxy2GbTAOM4qf0j8MBIF_Xj41yAL6s3n5dvs_WHm9vl1TprWYqfEYyMqmvTVtzQQjFcIFU0pmWobFDLsWHIIK0UZQ0niGquTKMQ5YZULUWa0AV4cfAdgv856TiKzsZWOyd77acoKkrT4SSNBXj-T5KgirM6kQvw9C9w46fQpysEIZwjXBRlguoD1AYfY9BGDMF2MuwFRmIuTGzE3IuYexFzYeJ3YWKXpE-O_lPTafVHeGwoAc-OgIytdCbIvrXxxBFck5LSOejlgdtap_f_HUDcvlt-nNdkkB0MbBz17mQgww_BKlqV4uv7G_F6vaKf7lZ34pr-AvaGwLI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229901445</pqid></control><display><type>article</type><title>Association between allopurinol and mortality in heart failure patients: a long-term follow-up study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wei, L. ; Fahey, T. ; Struthers, A. D. ; MacDonald, T. M.</creator><creatorcontrib>Wei, L. ; Fahey, T. ; Struthers, A. D. ; MacDonald, T. M.</creatorcontrib><description>Summary
Aims: The aim of the study was to explore the long‐term effect of allopurinol on mortality and cardiovascular hospitalisations in heart failure (HF) patients.
Methods: This is a population‐based cohort study using a record‐linkage database in Tayside, Scotland. A total of 4785 HF patients (4260 non‐users, 267 incident users and 258 prevalent users) were studied between 1993 and 2002.
Results: Compared with non‐users, low‐dose users in the incident group had a significant increased risk of all‐cause mortality, cardiovascular mortality and cardiovascular recurrence (adjusted HR, 1.60, 95%CI 1.26–2.03; 1.70, 1.29–2.23 and 1.44, 1.01–2.07). For the prevalent users, the adjusted HR were 1.27, 0.98–1.64; 1.43, 1.07–1.90 and 1.27, 0.91–1.76 respectively. There was no increased risk of outcome for high‐dose users when compared with non‐users (adjusted HR, 1.18, 0.84–1.66; 1.14, 0.76–1.71 and 1.36, 0.88–2.10 for the incident users, and 0.86, 0.64–1.15; 0.90, 0.64–1.26; and 1.27, 0.93–1.74 for the prevalent users respectively). High‐dose allopurinol was associated with reduced risk of all‐course mortality for prevalent users when compared with low‐dose (adjusted HR 0.65, 95%CI 0.42–0.99).
Conclusions: The prevalent high‐dose allopurinol use had a lower risk of mortality than the prevalent low‐dose use suggesting that allopurinol may be of benefit in HF patients.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1742-1241.2009.02118.x</identifier><identifier>PMID: 19691616</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Allopurinol - administration & dosage ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular Agents - administration & dosage ; Cardiovascular Diseases - mortality ; Cause of Death ; Dose-Response Relationship, Drug ; Drug therapy ; Epidemiology ; Female ; Follow-Up Studies ; General aspects ; Heart ; Heart failure ; Heart Failure - mortality ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Hospitalization ; Hospitalization - statistics & numerical data ; Humans ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Mortality ; Myocardial Infarction - mortality ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Recurrence ; Risk factors ; Scotland ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><ispartof>International journal of clinical practice (Esher), 2009-09, Vol.63 (9), p.1327-1333</ispartof><rights>2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><rights>Journal compilation © 2009 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6118-210fd88fc79f34d6140d4bfc605b0c91f60f0edd36b9203e9dfbd039f27c30e23</citedby><cites>FETCH-LOGICAL-c6118-210fd88fc79f34d6140d4bfc605b0c91f60f0edd36b9203e9dfbd039f27c30e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1742-1241.2009.02118.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1742-1241.2009.02118.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21825337$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19691616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, L.</creatorcontrib><creatorcontrib>Fahey, T.</creatorcontrib><creatorcontrib>Struthers, A. D.</creatorcontrib><creatorcontrib>MacDonald, T. M.</creatorcontrib><title>Association between allopurinol and mortality in heart failure patients: a long-term follow-up study</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
Aims: The aim of the study was to explore the long‐term effect of allopurinol on mortality and cardiovascular hospitalisations in heart failure (HF) patients.
Methods: This is a population‐based cohort study using a record‐linkage database in Tayside, Scotland. A total of 4785 HF patients (4260 non‐users, 267 incident users and 258 prevalent users) were studied between 1993 and 2002.
Results: Compared with non‐users, low‐dose users in the incident group had a significant increased risk of all‐cause mortality, cardiovascular mortality and cardiovascular recurrence (adjusted HR, 1.60, 95%CI 1.26–2.03; 1.70, 1.29–2.23 and 1.44, 1.01–2.07). For the prevalent users, the adjusted HR were 1.27, 0.98–1.64; 1.43, 1.07–1.90 and 1.27, 0.91–1.76 respectively. There was no increased risk of outcome for high‐dose users when compared with non‐users (adjusted HR, 1.18, 0.84–1.66; 1.14, 0.76–1.71 and 1.36, 0.88–2.10 for the incident users, and 0.86, 0.64–1.15; 0.90, 0.64–1.26; and 1.27, 0.93–1.74 for the prevalent users respectively). High‐dose allopurinol was associated with reduced risk of all‐course mortality for prevalent users when compared with low‐dose (adjusted HR 0.65, 95%CI 0.42–0.99).
Conclusions: The prevalent high‐dose allopurinol use had a lower risk of mortality than the prevalent low‐dose use suggesting that allopurinol may be of benefit in HF patients.</description><subject>Aged</subject><subject>Allopurinol - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Agents - administration & dosage</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cause of Death</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Heart Failure - mortality</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Hospitalization</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Myocardial Infarction - mortality</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Recurrence</subject><subject>Risk factors</subject><subject>Scotland</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV-L1DAUxYMo7u7oV5AgqE-t-dOmjQ8L66yzrgwqq-JjSJtEM6ZNTVpm5tubOsMIPoh5uRfyO4dzOQBAjHKc3stNjquCZJgUOCcI8RwRjOt8dw-cnz7up52yOisRxWfgIsYNQqQsa_QQnGHOOGaYnQN1FaNvrRyt72Gjx63WPZTO-WEKtvcOyl7BzodROjvuoe3hdy3DCI20bgoaDkmp-zG-ghI633_LRh06aHxy2GbTAOM4qf0j8MBIF_Xj41yAL6s3n5dvs_WHm9vl1TprWYqfEYyMqmvTVtzQQjFcIFU0pmWobFDLsWHIIK0UZQ0niGquTKMQ5YZULUWa0AV4cfAdgv856TiKzsZWOyd77acoKkrT4SSNBXj-T5KgirM6kQvw9C9w46fQpysEIZwjXBRlguoD1AYfY9BGDMF2MuwFRmIuTGzE3IuYexFzYeJ3YWKXpE-O_lPTafVHeGwoAc-OgIytdCbIvrXxxBFck5LSOejlgdtap_f_HUDcvlt-nNdkkB0MbBz17mQgww_BKlqV4uv7G_F6vaKf7lZ34pr-AvaGwLI</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Wei, L.</creator><creator>Fahey, T.</creator><creator>Struthers, A. D.</creator><creator>MacDonald, T. M.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200909</creationdate><title>Association between allopurinol and mortality in heart failure patients: a long-term follow-up study</title><author>Wei, L. ; Fahey, T. ; Struthers, A. D. ; MacDonald, T. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6118-210fd88fc79f34d6140d4bfc605b0c91f60f0edd36b9203e9dfbd039f27c30e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Allopurinol - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Agents - administration & dosage</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cause of Death</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Heart Failure - mortality</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Hospitalization</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Myocardial Infarction - mortality</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Recurrence</topic><topic>Risk factors</topic><topic>Scotland</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, L.</creatorcontrib><creatorcontrib>Fahey, T.</creatorcontrib><creatorcontrib>Struthers, A. D.</creatorcontrib><creatorcontrib>MacDonald, T. M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, L.</au><au>Fahey, T.</au><au>Struthers, A. D.</au><au>MacDonald, T. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between allopurinol and mortality in heart failure patients: a long-term follow-up study</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2009-09</date><risdate>2009</risdate><volume>63</volume><issue>9</issue><spage>1327</spage><epage>1333</epage><pages>1327-1333</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
Aims: The aim of the study was to explore the long‐term effect of allopurinol on mortality and cardiovascular hospitalisations in heart failure (HF) patients.
Methods: This is a population‐based cohort study using a record‐linkage database in Tayside, Scotland. A total of 4785 HF patients (4260 non‐users, 267 incident users and 258 prevalent users) were studied between 1993 and 2002.
Results: Compared with non‐users, low‐dose users in the incident group had a significant increased risk of all‐cause mortality, cardiovascular mortality and cardiovascular recurrence (adjusted HR, 1.60, 95%CI 1.26–2.03; 1.70, 1.29–2.23 and 1.44, 1.01–2.07). For the prevalent users, the adjusted HR were 1.27, 0.98–1.64; 1.43, 1.07–1.90 and 1.27, 0.91–1.76 respectively. There was no increased risk of outcome for high‐dose users when compared with non‐users (adjusted HR, 1.18, 0.84–1.66; 1.14, 0.76–1.71 and 1.36, 0.88–2.10 for the incident users, and 0.86, 0.64–1.15; 0.90, 0.64–1.26; and 1.27, 0.93–1.74 for the prevalent users respectively). High‐dose allopurinol was associated with reduced risk of all‐course mortality for prevalent users when compared with low‐dose (adjusted HR 0.65, 95%CI 0.42–0.99).
Conclusions: The prevalent high‐dose allopurinol use had a lower risk of mortality than the prevalent low‐dose use suggesting that allopurinol may be of benefit in HF patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19691616</pmid><doi>10.1111/j.1742-1241.2009.02118.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2009-09, Vol.63 (9), p.1327-1333 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733969273 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Allopurinol - administration & dosage Biological and medical sciences Cardiology. Vascular system Cardiovascular Agents - administration & dosage Cardiovascular Diseases - mortality Cause of Death Dose-Response Relationship, Drug Drug therapy Epidemiology Female Follow-Up Studies General aspects Heart Heart failure Heart Failure - mortality Heart failure, cardiogenic pulmonary edema, cardiac enlargement Hospitalization Hospitalization - statistics & numerical data Humans Kaplan-Meier Estimate Male Medical sciences Mortality Myocardial Infarction - mortality Public health. Hygiene Public health. Hygiene-occupational medicine Recurrence Risk factors Scotland Sodium Potassium Chloride Symporter Inhibitors - therapeutic use |
| title | Association between allopurinol and mortality in heart failure patients: a long-term follow-up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20allopurinol%20and%20mortality%20in%20heart%20failure%20patients:%20a%20long-term%20follow-up%20study&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Wei,%20L.&rft.date=2009-09&rft.volume=63&rft.issue=9&rft.spage=1327&rft.epage=1333&rft.pages=1327-1333&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1742-1241.2009.02118.x&rft_dat=%3Cproquest_cross%3E20796827%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229901445&rft_id=info:pmid/19691616&rfr_iscdi=true |